AR090472A1 - Virus de la enfermedad de marek modificado y vacunas elaboradas con el - Google Patents

Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Info

Publication number
AR090472A1
AR090472A1 ARP130100944A ARP130100944A AR090472A1 AR 090472 A1 AR090472 A1 AR 090472A1 AR P130100944 A ARP130100944 A AR P130100944A AR P130100944 A ARP130100944 A AR P130100944A AR 090472 A1 AR090472 A1 AR 090472A1
Authority
AR
Argentina
Prior art keywords
virus
disease
marek
transformed
mdv
Prior art date
Application number
ARP130100944A
Other languages
English (en)
Inventor
Pritchard Joyce
Mebatsion Teshome
Bublot Michel
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of AR090472A1 publication Critical patent/AR090472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vacuna eficaz para combatir la enfermedad de Marek, que puede elaborarse usando un virus de la enfermedad de Marek (MDV) recombinante de la cepa CV1988, que ha sido transformado con una construcción de ADN exógeno que comprende la secuencia de la repetición terminal larga de un virus de la reticuloendoteliosis. Este agente viral seguro es útil para generar una respuesta inmune de protección importante ante un ataque con un MDV virulento en un pollo, aunque no se caracteriza por una patogenicidad significativa. Las formulaciones apropiadas de esta vacuna que puede usarse en pollos comprenden dosis de este agente viral que son eficaces para la inmunización, junto con vehículos o diluyentes farmacéuticamente aceptables. Virus transformado, célula aislada.
ARP130100944A 2012-03-22 2013-03-22 Virus de la enfermedad de marek modificado y vacunas elaboradas con el AR090472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261614142P 2012-03-22 2012-03-22

Publications (1)

Publication Number Publication Date
AR090472A1 true AR090472A1 (es) 2014-11-12

Family

ID=48045766

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100944A AR090472A1 (es) 2012-03-22 2013-03-22 Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Country Status (28)

Country Link
US (3) US20130251737A1 (es)
EP (2) EP3326646A1 (es)
JP (1) JP2015512396A (es)
KR (5) KR20230145532A (es)
CN (1) CN104602706A (es)
AP (1) AP2014007955A0 (es)
AR (1) AR090472A1 (es)
BR (1) BR112014023398A8 (es)
CA (1) CA2868099C (es)
CR (1) CR20140432A (es)
DO (1) DOP2014000215A (es)
EA (1) EA030866B1 (es)
EC (1) ECSP14023407A (es)
ES (1) ES2663610T3 (es)
GE (1) GEP201706650B (es)
GT (1) GT201400199A (es)
HK (1) HK1255682A1 (es)
IL (1) IL234721B (es)
MA (1) MA37432A1 (es)
MX (1) MX355332B (es)
MY (1) MY169061A (es)
NL (1) NL301087I2 (es)
PE (1) PE20150323A1 (es)
PH (1) PH12014502085B1 (es)
TN (1) TN2014000393A1 (es)
UA (1) UA117345C2 (es)
WO (1) WO2013142377A2 (es)
ZA (1) ZA201406884B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201706650B (en) 2012-03-22 2017-03-27 Merial Inc Modified marek's disease virus, and vaccines made therefrom
CN106397602B (zh) * 2016-08-02 2019-06-18 青岛明勤生物科技有限公司 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642574A (en) 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US4160024A (en) 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine
NL8401120A (nl) 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US4895717A (en) 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
US4895718A (en) 1987-07-10 1990-01-23 The United States Of America, As Represented By The Secretary Of Agriculture Serotype 2 Marek's disease vaccine
EP0991426B2 (fr) 1997-06-30 2007-03-28 Institut Gustave Roussy Procede de transfert d'acide nucleique dans le muscle strie
US20050019348A1 (en) * 2003-07-21 2005-01-27 Reddy Sanjay M. Marek's disease virus vaccine
GEP201706650B (en) * 2012-03-22 2017-03-27 Merial Inc Modified marek's disease virus, and vaccines made therefrom
US9113301B1 (en) 2014-06-13 2015-08-18 Snapchat, Inc. Geo-location based event gallery

Also Published As

Publication number Publication date
US20130251737A1 (en) 2013-09-26
EP3326646A1 (en) 2018-05-30
MA37432A1 (fr) 2016-03-31
EA030866B1 (ru) 2018-10-31
KR20220008945A (ko) 2022-01-21
BR112014023398A2 (pt) 2017-07-11
US11510978B2 (en) 2022-11-29
IL234721B (en) 2018-05-31
TN2014000393A1 (en) 2015-12-21
MX355332B (es) 2018-04-16
NL301087I2 (nl) 2022-03-11
WO2013142377A2 (en) 2013-09-26
BR112014023398A8 (pt) 2022-08-16
KR20140146136A (ko) 2014-12-24
GT201400199A (es) 2018-10-15
ES2663610T3 (es) 2018-04-16
GEP201706650B (en) 2017-03-27
CA2868099C (en) 2020-12-15
CA2868099A1 (en) 2013-09-26
KR102586316B1 (ko) 2023-10-06
PH12014502085A1 (en) 2014-11-24
KR20230028595A (ko) 2023-02-28
HK1255682A1 (zh) 2019-08-23
PE20150323A1 (es) 2015-03-05
DOP2014000215A (es) 2015-04-15
US20230310589A1 (en) 2023-10-05
ECSP14023407A (es) 2015-06-30
PH12014502085B1 (en) 2014-11-24
ZA201406884B (en) 2015-11-25
JP2015512396A (ja) 2015-04-27
EA201401044A1 (ru) 2015-01-30
WO2013142377A3 (en) 2014-01-23
EP2827898B1 (en) 2017-12-20
CN104602706A (zh) 2015-05-06
UA117345C2 (uk) 2018-07-25
KR102503316B1 (ko) 2023-02-23
MY169061A (en) 2019-02-12
AP2014007955A0 (en) 2014-09-30
MX2014011388A (es) 2014-10-14
CR20140432A (es) 2015-01-09
KR20230145532A (ko) 2023-10-17
US20190216920A1 (en) 2019-07-18
EP2827898A2 (en) 2015-01-28
KR20190100431A (ko) 2019-08-28

Similar Documents

Publication Publication Date Title
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
PE20141482A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
WO2009092038A8 (en) Influenza dna vaccination and methods of use thereof
IL276210B2 (en) MERS-COV vaccine
CO2019011548A2 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos
AR079767A1 (es) Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
RU2016137119A (ru) Птичьи вирусные вакцины, которые являются стабильными в жидкой среде
AR110632A1 (es) Vectores del adenovirus canino
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
WO2017044895A3 (en) MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
AR122653A1 (es) Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogénicas, su producción y usos
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica
Fischer et al. A51 NEW INSIGHTS INTO PATHOGENS AND HOST DEFENSE: Live Attenuated Influenza Vaccines Elicit A Greater Innate Immune Response Than Antigenically Matched Seasonal Influenza Viruses During Infection Of Human Nasal Epithelial Cells
TH141649A (th) รีคอมบิแนนท์เวกเตอร์เฮอร์ปีส์ไวรัสของสัตว์ปีกและวัคซีนสำหรับการก่อภูมิคุ้มกันสปีชีส์ของนกน้ำ
PE20212213A1 (es) Cepas de vbi y usos de las mismas
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones
MX2016002399A (es) Virus recombinante de la enfermedad de newcastle que expresa una proteina inmunomoduladora como adyuvante molecular.
TH156282A (th) ไวรัสโรคมาเร็กซ์ที่ถูกดัดแปลงและวัคซีนที่ทำจากมัน
MX2015011485A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.

Legal Events

Date Code Title Description
FC Refusal